Objective This study aimed to establish a neural cell injury model in vitro by stimulating PC12 cells with lipopolysaccharide(LPS)and to examine the effects of astragaloside IV on key targets using high-throughput seq...Objective This study aimed to establish a neural cell injury model in vitro by stimulating PC12 cells with lipopolysaccharide(LPS)and to examine the effects of astragaloside IV on key targets using high-throughput sequence technology and bioinformatics analyses.Methods PC12 cells in the logarithmic growth phase were treated with LPS at final concentrations of 0.25,0.5,0.75,1,and 1.25 mg/mL for 24 h.Cell morphology was evaluated,and cell survival rates were calculated.A neurocyte inflammatory model was established with LPS treatment,which reached a 50%cell survival rate.PC12 cells were treated with 0.01,0.1,1,10,or 100µmol/L astragaloside IV for 24 h.The concentration of astragaloside IV that did not affect the cell survival rate was selected as the treatment group for subsequent experiments.NOS activity was detected by colorimetry;the expression levels of ERCC2,XRCC4,XRCC2,TNF-α,IL-1β,TLR4,NOS and COX-2 mRNA and protein were detected by RT-qPCR and Western blotting.The differentially expressed genes(DEGs)between the groups were screened using a second-generation sequence(fold change>2,P<0.05)with the following KEGG enrichment analysis,RT-qPCR and Western blotting were used to detect the mRNA and protein expression of DEGs related to the IL-17 pathway in different groups of PC12 cells.Results The viability of PC12 cells was not altered by treatment with 0.01,0.1,or 1µmol/L astragaloside IV for 24 h(P>0.05).However,after treatment with 0.5,0.75,1,or 1.25 mg/mL LPS for 24 h,the viability steadily decreased(P<0.01).The mRNA and protein expression levels of ERCC2,XRCC4,XRCC2,TNF-α,IL-1β,TLR4,NOS,and COX-2 were significantly increased after PC12 cells were treated with 1 mg/mL LPS for 24 h(P<0.01);however,these changes were reversed when PC12 cells were pretreated with 0.01,0.1,or 1µmol/L astragaloside IV in PC12 cells and then treated with 1 mg/mL LPS for 24 h(P<0.05).Second-generation sequencing revealed that 1026 genes were upregulated,while 1287 genes were downregulated.The DEGs were associated with autophagy,TNF-α,interleukin-17,MAPK,P53,Toll-like receptor,and NOD-like receptor signaling pathways.Furthermore,PC12 cells treated with a 1 mg/mL LPS for 24 h exhibited increased mRNA and protein expression of CCL2,CCL11,CCL7,MMP3,and MMP10,which are associated with the IL-17 pathway.RT-qPCR and Western blotting analyses confirmed that the DEGs listed above corresponded to the sequence assay results.Conclusion LPS can damage PC12 cells and cause inflammatory reactions in nerve cells and DNA damage.astragaloside IV plays an anti-inflammatory and DNA damage protective role and inhibits the IL-17 signaling pathway to exert a neuroprotective effect in vitro.展开更多
目的:基于网络药理学和分子对接方法,确定复方黄柏液治疗的Ⅲ度烧伤肉芽组织愈合的有效活性成分、关键靶点和潜在的药理学机制,并进行肉芽组织成纤维细胞的初步验证。方法:从公共数据库中药系统药理学分析平台(TCMSP)检索复方黄柏液组...目的:基于网络药理学和分子对接方法,确定复方黄柏液治疗的Ⅲ度烧伤肉芽组织愈合的有效活性成分、关键靶点和潜在的药理学机制,并进行肉芽组织成纤维细胞的初步验证。方法:从公共数据库中药系统药理学分析平台(TCMSP)检索复方黄柏液组成成分连翘、黄柏、金银花的有效成分和靶点;GeneCards、OMIM数据库检索“Ⅲ度烧伤”疾病相关靶点。通过生物信息学分析,包括蛋白质-蛋白质相互作用(Protein-proteininteraction,PPI)以及基因本体(Gene ontology,GO)和京都基因和基因组百科全书(Kyoto encyclopedia of genes and genomes,KEGG)分析,获得了关键的有效成分、核心靶点和相关信号通路;DiscoveryStudio分子对接分析有效成分化合物与靶蛋白的结合。0.5%的DMSO溶液处理的成纤维细胞记为对照组;槲皮素(40μmol/ml)处理的成纤维细胞记为槲皮素组。采用CCK8法、Transwell实验检测细胞增殖、迁移侵袭;WB试验检测细胞p-PI3K、p-Akt蛋白。结果:共筛选出74个有效成分,331个作用靶点,AKT1为潜在的治疗靶点,木犀草素、山柰酚、槲皮素、汉黄芩素、丹皮酚为潜在的候选药物。PI3K-AKT信号通路可能在复方黄柏液治疗Ⅲ度烧伤中发挥关键作用;分子对接表明槲皮素与AKT1结合最好。与对照组相比,槲皮素组成纤维细胞增殖、迁移侵袭均显著降低,p-PI3K、p-Akt蛋白表达也显著降低(P<0.05)。结论:复方黄柏液促进Ⅲ度烧伤患者肉芽组织形成的生物活性成分为槲皮素,潜在通路为PI3K-AKT信号通路,为复方黄柏液治疗Ⅲ度烧伤的研究提供了思路。展开更多
目的:探讨全髋关节置换术的CroweⅢ-Ⅳ型发育性髋关节发育不良(developmental dysplasia of the hip,DDH)患者的满意度及造成不满意的相关因素。方法:回顾性分析2013年3月至2018年3月行全髋关节置换术的169例CroweⅢ-Ⅳ型DDH患者,通过...目的:探讨全髋关节置换术的CroweⅢ-Ⅳ型发育性髋关节发育不良(developmental dysplasia of the hip,DDH)患者的满意度及造成不满意的相关因素。方法:回顾性分析2013年3月至2018年3月行全髋关节置换术的169例CroweⅢ-Ⅳ型DDH患者,通过微信进行调查问卷,调查患者对手术总体满意度、10项日常功能满意度和患者认为对自己日常生活影响比较大的前5个问题。手术前后采用髋关节Harris评分进行功能评价。结果:收到完整调查问卷145份,所有患者获随访,时间1~5(3.23±1.22)年。145例患者分成两组,其中对手术疗效满意的118例,不满意的27例,手术总体满意率81.38%(118/145)。患者认为对生活影响比较大的前5个问题分别是术后髋部疼痛,肢体明显不等长、行走、上下楼梯、蹲起。两组术前Harris评分比较,差异无统计学意义(P>0.05),不满意组术后Harris评分较低。术后髋关节疼痛、肢体不等长是影响手术不满意的直接因素。结论:采用全髋关节置换术治疗CroweⅢ-Ⅳ型DDH患者手术难度大;术后髋关节疼痛(轻度以上),肢体不等长(>2 cm)是术后不满意的独立危险因素。展开更多
基金supported by grants from Open Project of Gansu Traditional Chinese Medicine Research Center(No.zyzx-2020-10)Gansu Province Youth Science and Technology Foundation Program(No.21JR7RA652)+1 种基金Gansu Province Higher Education Research(No.2018A-049)Gansu Province Higher Education Research(No.2021B-163).
文摘Objective This study aimed to establish a neural cell injury model in vitro by stimulating PC12 cells with lipopolysaccharide(LPS)and to examine the effects of astragaloside IV on key targets using high-throughput sequence technology and bioinformatics analyses.Methods PC12 cells in the logarithmic growth phase were treated with LPS at final concentrations of 0.25,0.5,0.75,1,and 1.25 mg/mL for 24 h.Cell morphology was evaluated,and cell survival rates were calculated.A neurocyte inflammatory model was established with LPS treatment,which reached a 50%cell survival rate.PC12 cells were treated with 0.01,0.1,1,10,or 100µmol/L astragaloside IV for 24 h.The concentration of astragaloside IV that did not affect the cell survival rate was selected as the treatment group for subsequent experiments.NOS activity was detected by colorimetry;the expression levels of ERCC2,XRCC4,XRCC2,TNF-α,IL-1β,TLR4,NOS and COX-2 mRNA and protein were detected by RT-qPCR and Western blotting.The differentially expressed genes(DEGs)between the groups were screened using a second-generation sequence(fold change>2,P<0.05)with the following KEGG enrichment analysis,RT-qPCR and Western blotting were used to detect the mRNA and protein expression of DEGs related to the IL-17 pathway in different groups of PC12 cells.Results The viability of PC12 cells was not altered by treatment with 0.01,0.1,or 1µmol/L astragaloside IV for 24 h(P>0.05).However,after treatment with 0.5,0.75,1,or 1.25 mg/mL LPS for 24 h,the viability steadily decreased(P<0.01).The mRNA and protein expression levels of ERCC2,XRCC4,XRCC2,TNF-α,IL-1β,TLR4,NOS,and COX-2 were significantly increased after PC12 cells were treated with 1 mg/mL LPS for 24 h(P<0.01);however,these changes were reversed when PC12 cells were pretreated with 0.01,0.1,or 1µmol/L astragaloside IV in PC12 cells and then treated with 1 mg/mL LPS for 24 h(P<0.05).Second-generation sequencing revealed that 1026 genes were upregulated,while 1287 genes were downregulated.The DEGs were associated with autophagy,TNF-α,interleukin-17,MAPK,P53,Toll-like receptor,and NOD-like receptor signaling pathways.Furthermore,PC12 cells treated with a 1 mg/mL LPS for 24 h exhibited increased mRNA and protein expression of CCL2,CCL11,CCL7,MMP3,and MMP10,which are associated with the IL-17 pathway.RT-qPCR and Western blotting analyses confirmed that the DEGs listed above corresponded to the sequence assay results.Conclusion LPS can damage PC12 cells and cause inflammatory reactions in nerve cells and DNA damage.astragaloside IV plays an anti-inflammatory and DNA damage protective role and inhibits the IL-17 signaling pathway to exert a neuroprotective effect in vitro.
文摘目的:基于网络药理学和分子对接方法,确定复方黄柏液治疗的Ⅲ度烧伤肉芽组织愈合的有效活性成分、关键靶点和潜在的药理学机制,并进行肉芽组织成纤维细胞的初步验证。方法:从公共数据库中药系统药理学分析平台(TCMSP)检索复方黄柏液组成成分连翘、黄柏、金银花的有效成分和靶点;GeneCards、OMIM数据库检索“Ⅲ度烧伤”疾病相关靶点。通过生物信息学分析,包括蛋白质-蛋白质相互作用(Protein-proteininteraction,PPI)以及基因本体(Gene ontology,GO)和京都基因和基因组百科全书(Kyoto encyclopedia of genes and genomes,KEGG)分析,获得了关键的有效成分、核心靶点和相关信号通路;DiscoveryStudio分子对接分析有效成分化合物与靶蛋白的结合。0.5%的DMSO溶液处理的成纤维细胞记为对照组;槲皮素(40μmol/ml)处理的成纤维细胞记为槲皮素组。采用CCK8法、Transwell实验检测细胞增殖、迁移侵袭;WB试验检测细胞p-PI3K、p-Akt蛋白。结果:共筛选出74个有效成分,331个作用靶点,AKT1为潜在的治疗靶点,木犀草素、山柰酚、槲皮素、汉黄芩素、丹皮酚为潜在的候选药物。PI3K-AKT信号通路可能在复方黄柏液治疗Ⅲ度烧伤中发挥关键作用;分子对接表明槲皮素与AKT1结合最好。与对照组相比,槲皮素组成纤维细胞增殖、迁移侵袭均显著降低,p-PI3K、p-Akt蛋白表达也显著降低(P<0.05)。结论:复方黄柏液促进Ⅲ度烧伤患者肉芽组织形成的生物活性成分为槲皮素,潜在通路为PI3K-AKT信号通路,为复方黄柏液治疗Ⅲ度烧伤的研究提供了思路。
文摘目的:探讨全髋关节置换术的CroweⅢ-Ⅳ型发育性髋关节发育不良(developmental dysplasia of the hip,DDH)患者的满意度及造成不满意的相关因素。方法:回顾性分析2013年3月至2018年3月行全髋关节置换术的169例CroweⅢ-Ⅳ型DDH患者,通过微信进行调查问卷,调查患者对手术总体满意度、10项日常功能满意度和患者认为对自己日常生活影响比较大的前5个问题。手术前后采用髋关节Harris评分进行功能评价。结果:收到完整调查问卷145份,所有患者获随访,时间1~5(3.23±1.22)年。145例患者分成两组,其中对手术疗效满意的118例,不满意的27例,手术总体满意率81.38%(118/145)。患者认为对生活影响比较大的前5个问题分别是术后髋部疼痛,肢体明显不等长、行走、上下楼梯、蹲起。两组术前Harris评分比较,差异无统计学意义(P>0.05),不满意组术后Harris评分较低。术后髋关节疼痛、肢体不等长是影响手术不满意的直接因素。结论:采用全髋关节置换术治疗CroweⅢ-Ⅳ型DDH患者手术难度大;术后髋关节疼痛(轻度以上),肢体不等长(>2 cm)是术后不满意的独立危险因素。
